Cancer Therapy : Preclinical Antitumor Activity of YM 155 , a Selective Small-Molecule Survivin Suppressant , Alone and in Combination with Docetaxel in Human Malignant Melanoma Models

@inproceedings{Yamanaka2011CancerT,
  title={Cancer Therapy : Preclinical Antitumor Activity of YM 155 , a Selective Small-Molecule Survivin Suppressant , Alone and in Combination with Docetaxel in Human Malignant Melanoma Models},
  author={Kentaro Yamanaka and Takahito Nakahara and Tomohiro Yamauchi and Aya Kita and Masahiro Takeuchi and Fumiko Kiyonaga and Naoki Kaneko and Masao Sasamata},
  year={2011}
}
Purpose: Aggressive cell growth and chemoresistance are notorious obstacles in melanoma therapy. Accumulating evidence suggests that survivin is preferentially expressed in cancer cells and plays a crucial role in cell division and apoptosis dysfunction. Here, we evaluated the therapeutic potential of YM155, a selective survivin suppressant, alone and in combination with docetaxel using human melanoma models. Experimental Design: A375 and SK-MEL-5 humanmalignant melanoma cells were treated with… CONTINUE READING
6 Citations
29 References
Similar Papers

References

Publications referenced by this paper.
Showing 1-10 of 29 references

Antitumor effects of YM155, a novel survivin suppressant, against human aggressive non-Hodgkin lymphoma

  • A NTKita, K Yamanaka, K Nakano, M Nakata, M Mori, N Kaneko
  • Leuk Res
  • 2011

YM155, a novel survivin suppressant, enhances 10,000 Control YM155 Docetaxel

  • T YKNakahara, S Hatakeyama, A Kita, M Takeuchi, I Kinoyama, A Matsuhisa
  • Docetaxel
  • 2011
1 Excerpt

Similar Papers

Loading similar papers…